Rechallenging Statin Therapy in Veterans with Statin-Induced Myopathy Post Vitamin D Replenishment

Journal of Pharmacy Practice

Volumn 30, Issue 5, 2017, Pages 521-527

  Kang, Jenny H ^a,b   Nguyen, Quynh Nhu ^b   Mutka, Juleann ^b   Le, Quang A ^a,b  

^a WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

^b Jerry L Pettis Memorial VA Medical Center   (United States)

Author keywords

HMG CoA reductase inhibitors; pharmacist managed clinic; statin; statin induced myopathy; Vitamin D deficiency

Indexed keywords

ATORVASTATIN; CHOLESTEROL; COLECALCIFEROL; ERGOCALCIFEROL; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; VITAMIN D;

ADULT; AGED; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL OUTCOME; COHORT ANALYSIS; DOSE RESPONSE; DRUG TREATMENT FAILURE; FEMALE; HUMAN; LOADING DRUG DOSE; MALE; MYALGIA; MYOPATHY; PHARMACIST; RACE; RETROSPECTIVE STUDY; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION; BLOOD; CHEMICALLY INDUCED; MIDDLE AGED; MUSCLE DISEASE; OUTPATIENT DEPARTMENT; PUBLIC HOSPITAL; TRENDS; VETERAN;

AGED; CHOLESTEROL; COHORT STUDIES; FEMALE; HOSPITALS, VETERANS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MUSCULAR DISEASES; OUTPATIENT CLINICS, HOSPITAL; RETROSPECTIVE STUDIES; VETERANS; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 85029287994     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190016674407     Document Type: Article

References (23)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001; 285 (19): 2486-2497.
2. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014; 63: 2889-2934.
3. Jacobson TA, Ito MK, Maki KC, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1-executive summary. J Clin Lipidol. 2014; 8 (5): 473-488.
4. IMS Institute for Healthcare Informatics. Medicines use and spending in the US: a review of 2015 and outlook to 2020. 2016. https://morningconsult.com/wp-content/uploads/2016/04/IMS-Institute-US-Drug-Spending-2015.pdf. Accessed August 11, 2016.
5. Joy TR, Hegele RA,. Narrative review: statin-related myopathy. Ann Intern Med. 2009; 150 (12): 858-868.
6. Grundy SM, Cleeman JI, Merz CN, et al.Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol. 2004; 44 (3): 720-732.
7. Abd TT, Jacobson TA,. Statin-induced myopathy: a review and update. Expert Opin Drug Saf. 2011; 10 (3): 373-387.
8. Sathasivam S,. Statin induced myotoxicity. Eur J Intern Med. 2012; 23 (4): 317-324.
9. Thompson PD, Clarkson PM, Rosenson RS, National Lipid Association Statin Safety Task Force Muscle Safety Expert Panel. An assessment of statin safety by muscle experts. Am J Cardiol. 2006; 97 (8A): 69C-76C.
10. Gupta A, Thompson PD,. The relationship of vitamin D deficiency to statin myopathy. Atherosclerosis. 2011; 215 (1): 23-29. doi:10.1016/j.atherosclerosis.2010.11.039.
11. Glueck CJ, Budhani SB, Masineni SS, et al. Vitamin D deficiency, myositis-myalgia, and reversible statin intolerance. Curr Med Res Opin. 2011; 27 (9): 1683-1690.
12. Ahmed W, Naseer K, Glueck CJ, et al. Low serum 25 (OH) vitamin D levels (<32 ng/mL) are associated with reversible myositis-myalgia in statin-treated patients. Transl Res. 2009; 153 (1): 11-16.
13. Shannon J, John S, Ferrara J, et al. Statin-associated myopathy. US Pharm. 2012; 37 (2): 55-59.
14. Bruckert E, Hayem G, Dejager S, et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study. Cardiovasc Drugs Ther. 2005; 19 (6): 403-414.
15. Casciola-Rosen L, Mammen AL,. Myositis autoantibodies. Curr Opin Rheumatol. 2012; 24 (6): 602-608.
16. Michalska-Kasiczak M, Sahebkar A, Mikhailidis DP, et al.Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group. Analysis of vitamin D levels in patients with and without statin-associated myalgia-a systematic review and meta-analysis of 7 studies with 2420 patients. Int J Cardiol. 2015; 178: 111-116.
17. Holick MF1, Binkley NC, Bischoff-Ferrari HA, et al.Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011; 96 (7): 1911-1930.
18. Lee P, Greenfield JR, Campbell LV,. Vitamin D insufficiency-a novel mechanism of statin-induced myalgia? Clin Endocrinol (Oxf). 2009; 71 (1): 154-155.
19. Khayznikov M, Hemachrandra K, Pandit R, et al. Statin intolerance because of myalgia, myositis, myopathy, or myonecrosis can in most cases be safely resolved by vitamin D supplementation. N Am J Med Sci. 2015; 7 (13): 86-93.
20. Bitzur R, Kamari Y, Cohen H, et al. Intolerance to statins: mechanisms and management. Diabetes Care. 2013; 36 (suppl 2): S325-S330.
21. Bhattacharyya S, Bhattacharyya K, Maitra A,. Possible mechanisms of interaction between statins and vitamin D. Q J Med. 2012; 105 (5): 487-491.
22. Tomaszewski M, Stepien KM, Tomaszewska J, et al. Statin-induced myopathies. Pharmacol Rep. 2011; 63 (4): 859-866.
23. Wortsman J, Matsuoka LY, Chen TC, et al. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr. 2000; 72 (3): 690-693.